Summary
Quest Diagnostics Inc. (DGX) reported its second-quarter and first-half financial results for the period ending June 30, 2023. For the quarter, net revenues were $2.34 billion, a slight decrease of 4.7% year-over-year, impacted by a significant decline in COVID-19 testing revenues, though this was partially offset by growth in the base business and recent acquisitions. Diluted earnings per share (EPS) were $2.05, an increase of 4.6% compared to the prior year, showcasing improved profitability on a per-share basis despite lower overall revenues. For the first six months of the year, net revenues declined by 7.8% to $4.67 billion, primarily due to the ongoing normalization of COVID-19 testing volumes. However, the company's core diagnostic information services (DIS) business saw strong growth in its base operations. The company also made significant strategic acquisitions, including that of Haystack Oncology, Inc., and continued its Invigorate program aimed at cost structure improvement and performance enhancement. Despite a decrease in net cash from operating activities, the company maintained a strong liquidity position and reaffirmed its commitment to returning capital to shareholders through dividends and an active share repurchase program.
Financial Highlights
57 data points| Revenue | $2.34B |
| Cost of Revenue | $1.55B |
| Gross Profit | $792.00M |
| SG&A Expenses | $416.00M |
| Operating Expenses | $1.99B |
| Operating Income | $348.00M |
| Interest Expense | $39.00M |
| Net Income | $235.00M |
| EPS (Basic) | $2.08 |
| EPS (Diluted) | $2.05 |
| Shares Outstanding (Basic) | 112.00M |
| Shares Outstanding (Diluted) | 114.00M |
Key Highlights
- 1Net revenues for Q2 2023 decreased by 4.7% to $2.34 billion, primarily due to a 73% decline in COVID-19 testing revenues, though base business revenue grew 9.7% year-over-year.
- 2Diluted EPS for Q2 2023 increased by 4.6% to $2.05, indicating improved profitability per share despite lower total revenues.
- 3For the first six months of 2023, net revenues decreased by 7.8% to $4.67 billion, with COVID-19 testing revenues down significantly, while base business revenue grew 10.0%.
- 4The company completed two strategic acquisitions in the first half of 2023, including select assets of New York-Presbyterian's laboratory services business for $275 million and Haystack Oncology, Inc. for $392 million, bolstering its capabilities in advanced diagnostics.
- 5Net cash provided by operating activities for the six months ended June 30, 2023, was $538 million, a decrease from $882 million in the prior year, influenced by lower operating income and timing of COVID-19 testing revenue collections.
- 6The Invigorate program, aimed at cost reduction and performance improvement, incurred $26 million in pre-tax charges in the first half of 2023, with further charges expected in future periods.
- 7The company declared a quarterly dividend of $0.71 per share and has $1.3 billion remaining under its share repurchase authorization as of June 30, 2023.